C55 bacteriocin produced by ETB-plasmid positive Staphylococcus aureus strains is a key factor for competition with S. aureus strains

Microbiology and Immunology
Miki Kawada-MatsuoH Komatsuzawa

Abstract

Exfoliative toxin (ET) produced by Staphylococcus aureus is closely associated with the onset of bullous impetigo. To date, three ETs (ETA, ETB and ETD) have been identified. The gene encoding ETB is located in a plasmid designated pETB. Bacteriocin synthesis genes are also located in this plasmid and pETB-positive strains reportedly produce the C55 bacteriocin. In this study, the antibacterial activity against S. aureus strains of the bacteriocin produced by the pETB-positive strain TY4 was investigated. This bacteriocin demonstrated antibacterial activity against all pETB-negative but not pETB-positive strains, including TY4. Additionally, a TY4- strain from which the pETB plasmid had been deleted exhibited susceptibility to the bacteriocin. Further experiments revealed that two immunity factors (orf 46-47 and orf 48) downstream of the bacteriocin synthesis genes in the pETB plasmid are associated with immunity against the bacteriocin produced by TY4. The TY4- with orf46-47 strain exhibited complete resistance to bacteriocin, whereas the TY4- with orf48 strain exhibited partial resistance. Whether bacteriocin affects the proportion of each strain when co-cultured with S. aureus strains was also investigated. When TY4 or TY4- ...Continue Reading

References

Jun 1, 1983·Applied and Environmental Microbiology·S F Barefoot, T R Klaenhammer
Aug 26, 1998·The New England Journal of Medicine·F D Lowy
Sep 17, 1998·Journal of the American Academy of Dermatology·S M Manders
Dec 3, 1998·Applied and Environmental Microbiology·M A NavaratnaJ R Tagg
Jan 9, 1999·The New England Journal of Medicine·S BlotF Colardyn
Aug 10, 2000·Biopolymers·I F Nes, H Holo
Dec 15, 2000·Molecular Microbiology·T YamaguchiM Sugai
Jul 3, 2002·The Journal of Clinical Investigation·Yasushi HanakawaJohn R Stanley
Dec 16, 2004·The Journal of Clinical Investigation·Timothy J Foster
Oct 19, 2006·Journal of Bioscience and Bioengineering·Jun-ichi NagaoKenji Sonomoto
Oct 27, 2007·Molecular Microbiology·Min LiMichael Otto
Jan 20, 2009·Current Pharmaceutical Biotechnology·G Bierbaum, H-G Sahl
Feb 3, 2009·Molecular Microbiology·Lorraine A DraperR Paul Ross
Aug 11, 2011·Current Protein & Peptide Science·Srinivas SudaR Paul Ross
May 1, 2010·Toxins·Michal BukowskiGrzegorz Dubin
Oct 2, 2013·Antimicrobial Agents and Chemotherapy·Junzo HisatsuneMotoyuki Sugai

❮ Previous
Next ❯

Citations

Nov 1, 2020·Applied Microbiology and Biotechnology·Maria do Carmo de Freire BastosMarcus Lívio Varella Coelho

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.